The Effects of 6 Common Antidiabetic Drugs on Anti-PD1 Immune Checkpoint Inhibitor in Tumor Treatment
Diabetes and cancer are common diseases and are frequently diagnosed in the same individual. These patients need to take antidiabetic drugs while receiving antitumor drugs therapy. Recently, immunotherapy offers significant advances for cancer treatment. However, it is unclear whether antidiabetic d...
Saved in:
Main Authors: | Ze-Tao Zhan, Lu Liu, Ming-Zhen Cheng, Yi Gao, Wei-Jie Zhou |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2022-01-01
|
Series: | Journal of Immunology Research |
Online Access: | http://dx.doi.org/10.1155/2022/2651790 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Eosinophilic Asthma Secondary to Adjuvant Anti-PD-1 Immune Checkpoint Inhibitor Treatment in a Melanoma Patient
by: P. Kissoonsingh, et al.
Published: (2022-01-01) -
The impact of PD-L1 polymorphisms on the efficacy of immune checkpoint inhibitors depends on the tumor proportion score: a retrospective study
by: Keiichiro Suminaga, et al.
Published: (2025-02-01) -
PD-L1 positive platelets mediate resistance to immune checkpoint inhibitors in patients with colorectal cancer
by: Jiacheng Li, et al.
Published: (2025-01-01) -
Noninvasive Imaging of Immune Checkpoint Ligand PD-L1 in Tumors and Metastases for Guiding Immunotherapy
by: Samit Chatterjee PhD, et al.
Published: (2017-07-01) -
Advanced anaplastic thyroid carcinoma with positive expression of PD-L1 response to immune checkpoint inhibitors: A case report
by: Shanmin Fan, et al.
Published: (2025-01-01)